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Docetaxel is cost-effective and should be used as adjuvant treatment and considered 
as therapeutic option for MBC.
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COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN 
METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT 
SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA
Kim JH, Lee EK
Sook Myung Women’s University, Seoul, South Korea
OBJECTIVES: Bevacizumab, known as VEGF inhibitor, has demonstrated signiﬁcant 
activity when it is used with cytotoxic chemotherapy together in metastatic colorectal 
cancer(mCRC). However, bevacizumab is an expensive medication known as not 
cost-effectiveness with high ICER(Incremental Cost-Effectiveness Ratio) in other coun-
tries. The purpose of this study was to examine the economic efﬁciency of treating 
mCRC with bevacizumab plus chemotherapy versus chemotherapy alone from the 
perspective of the social aspects in Korea. METHODS: Markov model was developed 
to compare the cost and beneﬁts of adding bevacizumab to oxaliplatin plus FU/
LV(FOLFOX) or capecitabine plus FU/LV(CapeOX) with FOLFOX or CapeOX 
alone. We searched clinical documentation, extracted median time to progression and 
median overall survival from each chemotherapy, and calculated the transition prob-
ability and death rate per cycle. Model simulates costs and outcomes in hypothetical 
cohort of metastatic colorectal cancer for 5 years with 5% discount rate. We included 
that direct and non-direct medical cost(2009). The ICERs were calculated from incre-
mental life-years gained(LYG) and incremental costs between single and combination 
therapy. Sensitivity analyses were performed on crucial parameters. RESULTS: 
After markov model simulation for 5 years, FOLFOXbevacizumab gained 1.58 
years/patient and FOLFOX 1.42 years/patient, whereas CapeOXbevacizumab 1.57 
years/patient and CapeOX 1.31 years/patient. Total cost of FOLFOXbevacizumab, 
FOLFOX, CapeOXbevacizumab, CapeOX are W88,567,199($70,854), 
W73,938,752($59,151), W91,904,773($73,524), W43,864,530($35,092), respec-
tively. The ICERs of additional bevacizumab when combined with FOLFOX, CapeOX 
were W89,974,151 ($71,979), W181,331,641 ($145,065), respectively, per life year 
gained, proving very high in both case combination therapy. Sensitivity analysis 
showed that the price of bevacizumab is a key parameter of its cost-effectiveness. 
CONCLUSIONS: As a result, it is proven that the addition of bevacizumab to 
FOLFOX, CapeOX in mCRC patients is expensive given clinical beneﬁt in terms of 
LYG in Korea. This ﬁndings may offer one of the useful basic data selecting chemo-
therapy regimens in treating for mCRC.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in the 
UK. In 2007 the UK NHS introduced a CRC screening programme using the faecal 
occult blood test (FOBT) for biennial screening of individuals aged 60 to 69. CT 
colonography (CTC) is an alternative technology for CRC screening with the potential 
to prevent cancer by detecting pre-cancerous polyps as well as detecting cancer at an 
early stage. This economic analysis assessed the cost-effectiveness of CTC for CRC 
screening from the UK NHS perspective. METHODS: A state-transition Markov 
model was constructed to simulate the lifetime experience of a cohort of individuals 
screened under a range of scenarios using four different CRC screening technologies: 
FOBT, ﬂexible sigmoidoscopy, optical colonoscopy and CTC. The model estimated 
lifetime costs and health outcomes; the cost-effectiveness measure was incremental 
cost per Quality Adjusted Life Year (QALY). The impact of uncertainty in underlying 
model parameters was evaluated in one-way and probabilistic sensitivity analyses. 
RESULTS: CTC screening every 10 years for individuals aged 60–69 was less expen-
sive and yielded greater health beneﬁts (QALYs and life years) compared to no screen-
ing or the current UK programme of biennial FOBT screening. Compared to biennial 
FOBT, 10-yearly CTC screening for 60–69 year olds is estimated to avoid 661 more 
cases of CRC and 364 more deaths per 100,000 people invited for screening. CTC 
was cost-effective under a range of assumptions. The model ﬁt to observed epidemiol-
ogy data well, and was robust to changes in underlying parameter values. CONCLU-
SIONS: CTC has the potential to provide a cost-effective option for CRC screening 
and may be cost saving compared to the current programme of biennial FOBT.
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OBJECTIVES: Although several clinical and biological parameters are prognostic 
factors, their medico-economic impact in the prescription of erlotinib has never been 
evaluated. A French NCI prospective study aimed to determine the cost of manage-
ment of advanced NSCLC patients (pts) treated by erlotinib and to evaluate the cost-
effectiveness ratio in populations selected on clinical-guided or biomarkers-guided 
arguments. METHODS: Prospective cohort of consecutive advanced NSCLC pts 
newly treated by erlotinib and followed until progression or death. Direct medical 
costs, including erlotinib and hospitalization costs were computed from the health 
care system perspective with a time horizon of 2 years. Cost-effectiveness ratios (CER) 
were calculated as management cost divided by the number of days of life remaining 
(DOLR) when the treatment is initiated, in all patients, in clinical-selected patients 
(non/ex-smoking women with non-squamous cell carcinoma (SCC) histology) and in 
biomarker-selected patients. RESULTS: A total of 522 patients were enrolled between     
02/07 and 03/08. Median age was 62 years; 32% were females; 63% had adenocar-
cinoma. With a 15.5 months (mo.) median follow-up, median PFS and OS were 
respectively 2.4 and 5.6 mo. Mean management cost was 10284       o a8562 per patient, 
with a median of 170 days remaining to live at initiation of erlotinib treatment (a60 /
DOLR). Direct erlotinib cost represented 78% of the cost. Non-smoking women with 
non-SCC histology lived 133 days longer than other patients (279 and 146 days 
respectively), resulting in an extra-cost management of a2637 due to a longer erlotinib 
treatment. CER was however lower (a44/DOLR) in non-smoking women with non 
SCC histology than in other patients (a66/DOLR). CER of biomarkers-selected 
patients will be available for the congress. CONCLUSIONS: Clinical-guided argu-
ments allowed to identify patients with lower management costs per day of life 
remaining to live. Planned analyses would evaluate the impact of biomarkers in term 
of cost of management per day of life remaining.
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COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT 
WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY
Bonastre J, Koscielny S
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OBJECTIVES: Adjuvant chemotherapy is used to reduce the risk of relapse after 
surgery. Its limited efﬁcacy in breast cancer must be weighed against induced toxicities 
and cost. The selection of patients eligible for adjuvant chemotherapy is based 
on prognostic factors. Genomic signatures would improve patient selection for adju-       
vant chemotherapy and avoid overtreatment. The aim of this study is to compare the            
cost -effectiveness of different prognosis -based selection strategies in the French 
context. METHODS: We used a model -based simulation. Population characteristics, 
survival and hospital costs (chemotherapy, chemotherapy -induced toxicities and 
relapses) were estimated using a patient -level data set from a retrospective cohort 
of patients followed -up at Gustave Roussy Institute since 1990. All patients 
were node -negative and metastasis -free after initial surgery. The other model param-
eters (chemotherapy efﬁcacy, sensitivity and speciﬁcity of prognosis -based selection 
strategies) were obtained from literature. The cost analysis was conducted from a 
third -party payer’s perspective. We used a strategy with no adjuvant chemotherapy 
as a reference for cost -effectiveness comparisons. RESULTS: The retrospective 
cohort study consisted of 910 women with breast cancer. The mean age was 57 
(range: 23–93). Thirty-one percent of patients were Scarff -Bloom grade I, 43% 
grade II and 19% grade III (7% grade missing). The mean tumor size was 19 mm 
(range: 1–120). Thirty-two percent of the women received adjuvant chemotherapy 
alone or combined with another adjuvant treatment. The median follow-up after 
surgery was 87 months. The median survival time was 209 months. The distant relapse 
rate was 10.7%. The cost of adjuvant chemotherapy was a3,083 (standard deviation: 
a307) and the cost of distant relapse a33,692 (range: a847–a112,710). Cost -effective-
ness analysis is in progress. Results will be available for the meeting. CONCLUSIONS: 
This is the ﬁrst French study to assess the cost -effectiveness of using prognostic 
information to select women eligible for adjuvant chemotherapy in early breast 
cancer.
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod compared 
to no treatment in patients with superﬁcial basal cell carcinoma and contraindication 
to surgical intervention and cryotherapy in Poland. METHODS: This analysis was 
based on a decision model regarding clinical effects of imiquimod in comparison to 
placebo (vehicle cream), obtained from randomized clinical trials. The population was 
deﬁned as adult patients with superﬁcial basal cell carcinoma (sBCC) and contraindi-
cation to surgical intervention/cryotherapy, also patients, who do not give consent to 
these forms of treatment. Clinical and histological complete clearance were assessed 
as health outcomes. Direct medical costs of the analysed therapies were estimated from 
the perspective of both payers in Poland (National Health Fund and patient). We 
included costs of medication, clinic visits and diagnostic assessments. Time horizon 
of the analysis was 18 weeks. Treatment was assumed as once a day 5x/week for 6 
weeks. Costs and effects were not discounted. RESULTS: Probability of complete 
clearance, assessed clinically and histologically was 0.751 for patients treated with 
imiquimod and 0.017 when placebo was used. Probability of histological complete 
clearence was 0.822 and 0.031, respectively. Total costs of imiquimod therapy were 
estimated at 1,075.30 PLN, while costs of no treatment were 174.80 PLN. Incremental 
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cost-effectiveness ratio (ICER) for the comparison of imiquimod versus no treatment 
was 1,227 PLN per gained complete clearance assessed clinically and histologically, 
and 1,138 PLN per gained complete clearence assessed only histologically. CONCLU-
SIONS: Imiquimod is more effective and more expensive than no treatment in patients 
with superﬁcial basal cell carcinoma and contraindication to surgical intervention and 
cryotherapy. ICER value is below the acceptable threshold, therefore imiquimod 
therapy is considered as cost-effective treatment in Poland.
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COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT 
FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
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OBJECTIVES: To evaluate the cost-effectiveness of anastrozole (1 mg/day) versus 
tamoxifen (20 mg/day) as adjuvant treatment for early stages breast cancer in post-
menopausal women. METHODS: Cost-effectiveness analysis was performed. Markov 
model was built based on the results of ATAC and ARNO 95 studies. Two strategies 
of adjuvant therapy—initial therapy with anastrozole and switching to anastrozole 
after two years treatment with tamoxifen were evaluate in the model, total duration 
of adjuvant therapy followed in the model was 5 years. The time horizon was equal 
to patient’s life expectancy. RESULTS: The results demonstrated that initial adjuvant 
therapy with anastrozole is cost-effectiveness in patients with high risk of relapse and 
also in the group of patients younger then 55 years. The cost-effectiveness ratio in the 
basis variant (population included into ATAC-study, age at the start of adjuvant 
therapy—65 years) was 1161.4 thousand Rub/QALY (a25,800/QALY). In early debut 
of cancer at the age of  55 years, the cost-effectiveness ratio was 728.8 thousand 
Rub/QALY (a16,200/QALY). From the economic point of view the effective therapy 
scheme is switching patients to anastrozole after two years of tamoxifen treatment. 
The cost-effectiveness ratio of this scheme is estimated from 624,6 thousand Rub/
QALY (a13,900/QALY) in patients at the age of 55 years to 1209.7 thousand Rub/
QALY (a26,900/QALY) in patients at the age of 70 years. In the basis variant (popula-
tion included into ARNO 95-study age at the start of adjuvant therapy—60 years) 
the ratio was 776.4 thousand Rub/QALY (a17,300/QALY). CONCLUSIONS: The 
switching the patients in postmenopause to anastrozole after two years of tamoxifen 
treatment may be considered reasonable from the economic point of view in Russia. 
The initial adjuvant treatment with anastrozole in patients with high risk of relapse, 
not belonging to elder age groups, is also economically reasonable.
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COST-EFFECTIVENESS OF SHORT-ACTING OPIOIDS FOR 
BREAKTHROUGH PAIN IN CANCER PATIENTS—A SCOTTISH-BASED 
DECISION-ANALYSIS MODEL
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OBJECTIVES: A decision-analysis model parameterised for Scotland was used to 
evaluate the cost-effectiveness of intranasal fentanyl spray (INFS, Instanyl®) compared 
with oral transmucosal fentanyl citrate lozenge (OTFC, Actiq®) and oral transmucosal 
fentanyl buccal tablet (FBT, Effentora®) for the treatment of BTCP. METHODS: The 
model estimated costs and beneﬁts associated with INFS, OTFC and FBT. Relative           
analgesic efﬁcacy of the interventions was derived from a meta-analysis of six ran-
domised controlled trials. The percentage of BTCP avoided was estimated from the 
pain intensity (PI) course of a BTCP episode with and without treatment. Resource 
use and quality of life gains were estimated based on reductions in PI. The relationship 
between PI and utility was derived from a time-trade off study in the UK general 
population. Resource use and unit cost data were obtained from the literature and 
validated by clinical experts. Uncertainty in the source data was incorporated by        
means of one-way sensitivity analyses, probabilistic sensitivity analyses and different 
scenario analyses. RESULTS: For the base-case scenario, 3 BTCP episodes/day, a 
background PI of 2, a time-horizon of 365 days and equal prices for INFS and OTFC 
irrespective of dosage were assumed. With INFS, 55% of BTCP (95% Uncertainty 
Interval: 45–66%) was avoided, greater than expected with OTFC (29%; 21–39%) 
or FBT (31%; 25–39%). INFS was dominant versus OTFC and cost-effective versus 
FBT. Despite the uncertainty in the source data, there is a          99% probability that INFS 
is the most cost-effective intervention. Sensitivity and scenario analyses did not change 
the main conclusion. CONCLUSIONS: Greater efﬁcacy of INFS in pain reduction is 
expected to reduce medical resource use and result in cost-savings for health care 
providers and quality of life gains for patients. INFS is a cost-effective treatment for 
BTCP compared with OTFC and FBT in Scotland.
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COST EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH 
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OBJECTIVES: Based on results from the HERceptin Adjuvant Trial (HERA) with a 
median follow-up time of 1 year, trastuzumab is licensed and reimbursed for the 
treatment of HER2 early breast cancer (EBC) in Italy since 2006. As the risk of 
recurrence reduces overtime, hazard ratios in breast cancer trials usually increase as 
more follow-up data is available. Longer term follow-up data were recently reported 
for 2 and 4 years, the latter though being heavily confounded by extensive cross-over 
of the HERA comparator arm and hence unusable. The objective of this analysis was 
therefore to determine the cost effectiveness of 1-year treatment with trastuzumab vs 
observation, based on results from the 2-year follow up data. METHODS: A pub-
lished Markov model based on the initial HERA results was revised and updated to 
incorporate the hazard ratios from the 2-year follow up data to reﬂect trastuzumab’s 
impact on disease progression. The treatment effect reported was applied for the ﬁrst 
4 years of the model. An Italian health care payer perspective was adopted. Medication 
and acquisition costs were taken from published sources whereas health state and 
event costs were derived from costing study conducted in Tuscany. A lifetime horizon 
was chosen. Incremental cost-effectiveness ratios were expressed as cost per quality 
adjusted life year (QALY). Costs and QALYs were discounted at 3.0% p.a. Sensitivity 
analyses were performed. RESULTS: The analysis showed that after completion of 
adjuvant chemotherapy, treatment with trastuzumab resulted into additional 1.81 life 
years and 1.62 QALYS gained per patient compared to observation only, at an incre-
mental mean total cost of a18,022. The ICER was estimated at a11,131/QALY, which 
is well in line with previously published analyses. CONCLUSIONS: Using more recent 
data from the HERA trial, Trastuzumab was determined to remain a cost effective 
treatment option for HER2ve EBC in the Italian setting.
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OBJECTIVES: Following broadening of the EMEA license for ﬁrst-line treatment 
of previously untreated patients with chronic lymphocytic leukaemia (CLL) with     
rituximab added to chemotherapy, we evaluated the cost-effectiveness of rituximab 
in combination with commonly used chemotherapy regimen of ﬂudarabine plus 
cyclophosphamide (R-FC) versus ﬂudarabine plus cyclophosphamide (FC) from the 
perspective of the Spanish national health care system. METHODS: A three stage 
Markov model including progression-free survival (PFS), progression state and mortal-
ity was developed using published results from the randomized clinical trial CLL-8 
evaluating PFS in patients with CLL. Rates of disease progression were derived       
from a Weibull model, mortality rates were obtained from Kaplan-Meier and Spanish 
age-speciﬁc mortality tables. Patient elicited utilities were applied to PFS and pro-
gressed health states. The cost of drugs, supportive care, and quality-adjusted life 
years (QALY) were estimated over a period of 10 years, the median survival for CLL, 
and discounted at 3.5 per annum. Univariate and probabilistic (Monte Carlo simula-
tion) sensitivity analysis were performed. RESULTS: The addition of rituximab to 
chemotherapy increased life-years gained (LYG) and QALYs by 0.669 and 0.617 
years per patient, respectively, compared to chemotherapy alone. The incremental 
cost per LYG and QALY gained was a17,726 and a19,220, respectively. Cost-effective 
results were obtained with Monte Carlo simulation. Univariate sensitivity analyses 
indicated the results were robust, and most sensitive to time horizon, with a threshold 
value at year 7, from which the R-FC regimen is cost-effective. CONCLUSIONS: 
The model demonstrated that the addition of rituximab to ﬂudarabine plus cyclophos-
phamide (FC) regimen increased life and quality-adjusted life expectancy and is a 
cost-effective ﬁrst-line treatment option for patients with chronic lymphocytic 
leukaemia.
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COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF 
ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 
erlotinib compared to docetaxel for the treatment of advanced non small cell lung 
cancer (NSCLC) in China. METHODS: A Markov health-state model was designed 
to estimate the direct medical costs and outcomes (life years and QALYs gained) of 
treating advanced NSCLC. The model included three health states—progression free 
survival (PFS), post progression free survival (PPF) and death. The evolution of a 
cohort of patients was simulated along 2 years with monthly cycles. Survival and time 
to progression were retrieved from 2 pivotal clinical trials. From the perspective of 
China’s health insurance system, resource use was calculated based on a questionnaire 
survey from clinical expert panels. A discounting rate at 3% was used to discount 
medical costs happening at different years. A univariate sensitivity analysis was per-
formed to understand the key drivers and general sensitivity of the model. RESULTS: 
The model results showed that the utilization of erlotinib treatment in NSCLC can 
prolong 0.047 QALYs (0.038 life years), compared to the docetaxel treatment. The 
total cost per patient was lower with erlotinib (US$23,351) than with docetaxel 
(US$24,846). The lower cost and better efﬁcacy associated with erlotinib makes it a 
dominant treatment strategy in comparison to docetaxel. CONCLUSIONS: According 
to this model, erlotinib is more cost-effective than docetaxel in treating advanced 
NSCLC, with savings for the China’s health insurance system.
